B of A Securities Initiates Coverage On Amphastar Pharma with Neutral Rating, Announces Price Target of $63
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Jason Gerberry has initiated coverage on Amphastar Pharmaceuticals with a Neutral rating and set a price target of $63 for the company's stock.
November 17, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Amphastar Pharmaceuticals receives a Neutral rating from B of A Securities with a price target of $63.
The initiation of coverage by a major analyst with a Neutral rating typically does not exert a strong influence on a stock's price in the short term. However, the setting of a price target can sometimes provide a benchmark for investors, potentially influencing investment decisions.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100